New antibody drug shows promise for tough kidney disease
NCT ID NCT05398653
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug, MIL62, in 94 adults with primary membranous nephropathy, a serious kidney condition. The goal was to see if MIL62 is safe and can help reduce protein in the urine better than the standard drug cyclosporine. Participants received either MIL62 or cyclosporine and were followed for up to 104 weeks to check for remission and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China